A registration-enabling study of eganelisib in patients with advanced urothelial cancer
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Eganelisib (Primary)
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 27 Jul 2021 According to an Infinity Pharmaceuticals media release, an update on this program is expected by the end of 2021.
- 16 Mar 2021 According to an Infinity Pharmaceuticals media release, after the initial feedback from the U.S. Food and Drug Administration (FDA), additional trial details are expected by the end of Q2 2021, and will likely focus on PD-L1 low aUC patients with a 30 mg QD dose of eganelisib.
- 08 Jan 2021 New trial record